Immune checkpoint inhibitors (ICIs) targeting CTLA‐4 and the PD‐1/PD‐L1 axis have shown unprecedented and durable responses in cancer patients by restoring the antitumor activities of T cells [1]. The gene discussed is PDCD1; the disease is cancer.